| Revenue growth | FY26: 43%; FY27 target: ₹380-400 Cr; FY28 target: ₹700-800 Cr. |
|---|---|
| Margins | EBITDA margin target 25-30% on consolidated basis. |
| Order book | Current visibility around ₹280-300 Cr for FY27. |
| Demand visibility | Clear visibility for ₹280-300 Cr order book in FY27. |
| Management confidence | Bullish on demand and revenue targets despite supply chain headwinds. |
Growth
FY26 Revenue ₹172.22 Cr (+42.98%), EBITDA ₹47.77 Cr (+47.55%), PAT ₹29.09 Cr (+41.77%).
Outlook
FY27 revenue guidance ₹380-400 Cr; FY28 target ₹700-800 Cr. Plan ₹130 Cr Capex.
Risks
Raw material price volatility, global supply chain disruptions, and high receivable days (130-140).
Last quarter's promises, checked
Delivered
- FY26 Revenue ₹170-180 Cr → delivered ₹172.22 Cr (= BEAT)
- Q3 EBITDA margin 35% → delivered 35.06% (= BEAT)
- Acquisition of Apiqo Organic → delivered completed (= BEAT)
Partly delivered
- CDMO validation of 3 molecules → delivered 1 dispatched, 2 pending Q1FY27 (= PARTIAL)
Missed
- Working capital days 180-185 by FY26 end → delivered 290 days (= MISS)
Earnings Call filed with NSE, NSE: AHCL. Summary written with AI assistance from the document.
Anlon Healthcare Ltd: key numbers
- Share price
- ₹31.51
- Market cap
- ₹167.5 Cr
- Revenue (annual)
- ₹172.0 Cr
- Net profit (annual)
- ₹28.51 Cr
- P/E (TTM)
- 5.3×Sector 50.4×
- Promoter holding
- 52.68%+0.00% QoQ
- FII holding
- 1.67%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Anlon Healthcare Ltd
All →Anlon Healthcare Merger & Restructuring
Anlon Healthcare incorporated ANLON Healthcare Nigeria Limited, holding 90% stake. The subsidiary aims to expand pharmaceutical and healthcare operations across 16 West African countries.
Anlon Healthcare Acquisition
Anlon Healthcare's AGM approved acquiring Apiqo Organics and Bizotic Lifescience stakes via share swap. The filing adds preferential issue pricing of ₹17.85 per share.
Anlon Healthcare Price Movement Clarification
Anlon Healthcare responded to NSE/BSE surveillance queries stating no undisclosed information explains the price movement. The company attributes the move to market-driven factors.
Anlon Healthcare Credit Rating
Brickwork Ratings assigned BWR BBB/Stable to Anlon Healthcare's ₹23.60 Crore fund-based term loan. The rating reflects improved profitability and low leverage following the company's 2025 IPO.
Anlon Healthcare Annual General Meeting
Anlon Healthcare Limited held its 13th Annual General Meeting on September 05, 2025. Shareholders considered financial statements, director appointments, and a preferential issue of equity shares.
Anlon Healthcare Investor Presentation: Key Takeaways
Anlon Healthcare Q1 FY27 results show strong top-line growth following the acquisition of Remember India Health Links, though EBITDA margins faced temporary pressure from surging raw material costs and consolidation expenses.
- Call
- Guides 30% growth